Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Prostatic Neoplasms 3 Lung Neoplasms 2 Carcinoma, Renal Cell 2 Weight Loss 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Apnea Syndromes 1 Sezary Syndrome 1 Sarcoma 1 Recurrence 1 Overweight 1 Obesity, Morbid 1 Obesity 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasm Metastasis 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Hypertension 1 Hyperlipidemias 1 Hemangioma 1 Gastroesophageal Reflux 1 Eczema 1 Disease 1 Digestive System Diseases 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Dermatitis, Atopic 1 Collagen Diseases 1

Interventions

Dexamethasone 808 Bortezomib 446 Lenalidomide 430 Cyclophosphamide 336 Melphalan 250 Calcium Dobesilate 236 daratumumab 217 pomalidomide 201 carfilzomib 181 fludarabine phosphate 131 Thalidomide 121 fludarabine 118 Peripheral Blood Stem Cell Transplantation 117 Filgrastim 111 ixazomib 85 Mycophenolic Acid 85 Granulocyte Colony-Stimulating Factor 84 Busulfan 83 Whole-Body Irradiation 80 Tacrolimus 75 dexamethasone acetate 74 Cyclosporine 67 Prednisone 64 dexamethasone 21-phosphate 63 isatuximab 62 elotuzumab 60 auricularum 57 Antilymphocyte Serum 55 belantamab mafodotin 54 Etoposide 52

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Urine Specimen Collection × Clear all

NCT04111809 2025-09-25

AMBROBiMM

Assistance Publique - Hôpitaux de Paris

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡